Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Raw Materials (2019 - 2025)

Historic Raw Materials for Ptc Therapeutics (PTCT) over the last 7 years, with Q3 2025 value amounting to $2.2 million.

  • Ptc Therapeutics' Raw Materials fell 1804.24% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 1804.24%. This contributed to the annual value of $2.5 million for FY2024, which is 16659.66% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Raw Materials stood at $2.2 million, which was down 1804.24% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Raw Materials registered a high of $2.7 million during Q3 2024, and its lowest value of $678000.0 during Q1 2021.
  • Its 5-year average for Raw Materials is $1.4 million, with a median of $1.2 million in 2022.
  • Per our database at Business Quant, Ptc Therapeutics' Raw Materials plummeted by 2691.54% in 2023 and then soared by 20187.43% in 2024.
  • Ptc Therapeutics' Raw Materials (Quarter) stood at $1.4 million in 2021, then decreased by 23.98% to $1.1 million in 2022, then dropped by 11.69% to $952000.0 in 2023, then soared by 166.6% to $2.5 million in 2024, then fell by 11.58% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.2 million for Q2 2025, and $2.1 million during Q1 2025.